［1］James FR，Wootton S，Jackson A，et al.Obesity in breast cancer-what is the riks factor［J］?Eur J Cancer，2015，51(6)：705-720.
［2］Khodari W，Sedrati A，Naisse I，et al.Impact of loco-regional treatment on metastatic breast cancer outcome：A review［J］.Crit Rev Oncol Hematol，2013，87(1)：69-79.
［3］Calle EE，Rodriguez C，Walker-Thurmond K，et al.Overweight，obesity，and mortality from cancer in a prospectively studied cohort of U.S.adults［J］.N Engl J Med，2003，348(17)：1625-1638.
［4］Calle EE，Kaaks R.Overweight，obesity and cancer：Epidemiological evidence and proposed mechanisms［J］.Nat Rev Cancer，2004，4(8)：579-591.
［5］Renehan AG，Tyson M，Egger M，et al.Body-mass index and incidence of cancer：A systematic review and Meta-analysis of prospec-tive observational studies［J］.Lancet，2008，371(9612)：569-578.
［6］Wiseman M.The second world cancer research fund/American institute for cancer research expert report.Food，nutrition，physical activity，and the prevention of cancer：A global perspective［J］.Proc Nutr Soc，2008，67(3)：253-256.
［7］Vainio H，Kaaks R，Bianchini F.Weight control and physical activity in cancer prevention：International evaluation of the evidence［J］.Eur J Cancer Prev，2002，11(2)：94-100.
［8］Reeves GK，Pirie K，Beral V，et al.Cancer incidence and mortality in relation to body mass index in the million women study：Cohort study［J］.BMJ，2007，335(7630)：1134.
［9］Wolin KY，Carson K，Colditz GA.Obesity and cancer［J］.Oncologist，2010，15(6)：556-565.
［10］Ma J，Li H，Giovannucci E，et al.Prediagnostic body mass index，plasma C-peptide concentration，and prostate cancer-spe-cific mortality in men with prostate cancer：A long-term survival analysis［J］.Lancet Oncol，2008，9(11)：1039-1047.
［11］De Pergola G，Silvestris F.Obesity as a major risk factor for cancer［J］.J Obes，2013，2013：291546.
［12］Divella R，De Luca R，Abbate I，et al.Obesity and cancer：The role of adipose tissue and adipo-cytokines-induced chronic inflammation［J］.J Cancer，2016，7(15)：2346-2359.
［13］Spindler SR.Rapid and reversible induction of the longevity，anticancer and genomic effects of caloric restriction［J］.Mech Ageing Dev，2005，126(9)：960-966.
［14］Pallavi R，Giorgio M，Pelicci PG.Insights into the beneficial effect of caloric/dietary restriction for a healthy and prolonged life［J］.Front Physiol，2012，3：318.
［15］Imayama I，Ulrich CM，Alfano CM，et al.Effects of a caloric restriction weight loss diet and exercise on inflammatory biomark-ers in overweight/obese postmenopausal women：A randomized controlled trial［J］.Cancer Res，2012，72(9)：2314-2326.
［16］Semenza GL.Hypoxia-inducible factors in physiology and medicine［J］.Cell，2012，148(3)：399-408.
［17］Vaupel P，Hockel M，Mayer A.Detection and characterization of tumor hypoxia using PO2 histography［J］.Antioxid Redox Signal，2007，9(8)：1221-2335.
［18］Semenza GL.Advances in cancer biology and therapy［J］.J Mol Med(Berl)，2013，91(4)：409.
［19］Cairns R，Papandreou I，Denko N.Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment［J］.Mol Cancer Res，2006，4(2)：61-70.
［20］Guppy M.The hypoxic core：A possible answer to the cancer paradox［J］.Biochem Biophys Res Commun，2002，299(4)：676-680.
［21］Lum JJ，Bui T，Gruber M，et al.The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis［J］.Genes Dev，2007，21(9)：1037-1049.
［22］Lopez-Lazaro M.The warburg effect：Why and how do cancer cells activate glycolysis in the presence of oxygen［J］?Anticancer Agents Med Chem，2008，8(3)：305-312.
［23］Milane L，Duan Z，Amiji M.Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning［J］.Cancer Cell Int，2011，11：3.
［24］Vaapil M，Helczynska K，Villadsen R，et al.Hypoxic conditions induce a cancer-like phenotype in human breast epithelial cells［J］.PLoS One，2012，7(9)：e46543.
［25］Hosogai N，Fukuhara A，Oshima K，et al.Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation［J］.Diabetes，2007，56(4)：901-911.
［26］Ye J，Gao Z，Yin J，et al.Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice［J］.Am J Physiol Endocrinol Metab，2007，293(4)：E1118-1128.
［27］Fridlyand LE，Philipson LH.Reactive species and early manifestation of insulin resistance in type 2 diabetes［J］.Diabetes Obes Metab，2006，8(2)：136-145.
［28］Gehmert S，Gehmert S，Bai X，et al.Limitation of in vivo models investigating angiogenesis in breast cancer［J］.Clin Hemorheol Microcirc，2011，49(1-4)：519-526.
［29］Yao-Borengasser A，Monzavi-Karbassi B，Hedges RA，et al.Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells［J］.Oncol Rep，2015，33(6)：2689-2694.
［30］Seifert A，Taubert H，Hombach-Klonisch S，et al.TCDD mediates inhibition of p53 and activation of ERalpha signaling in MCF-7 cells at moderate hypoxic conditions［J］.Int J Oncol，2009，35(2)：417-424.
［31］Denzel MS,Hebbard LW,Shostak G,et al. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer［J］.Clin Cancer Res,2009,15(10):3256-3264.
［32］Gatterer H，Haacke S，Burtscher M，et al.Normobaric intermittent hypoxia over 8 months does not reduce body weight and metabolic risk factors-a randomized，single blind，placebo-controlled study in normobaric hypoxia and normobaric sham hypoxia［J］.Obes Facts，2015，8(3)：200-209.
［33］Mantzoros C，Petridou E，Dessypris N，et al.Adiponectin and breast cancer risk［J］.J Clin Endocrinol Metab，2004，89(3)：1102-1107.
［34］Chen DC，Chung YF，Yeh YT，et al.Serum adiponectin and leptin levels in Taiwanese breast cancer patients［J］.Cancer Lett，2006，237(1)：109-114.
［35］Pahlman S，Lund LR，Jogi A.Differential HIF-1alpha and HIF-2alpha expression in mammary epithelial cells during fat pad invasion，lactation，and involution［J］.PLoS One，2015，10(5)：e0125771.
［36］Schwab LP，Peacock DL，Majumdar D，et al.Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer［J］.Breast Cancer Res，2012，14(1)：R6.
［37］Galindo-Hernandez O，Villegas-Comonfort S，Candanedo F，et al.Elevated con-centration of microvesicles isolated from peripheral blood in breast cancer patients［J］.Arch Med Res，2013，44(3)：208-214.
［38］Chaturvedi P，Gilkes DM，Takano N，et al.Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment［J］.Proc Natl Acad Sci USA，2014，111(20)：E2120-2129.
［39］Luo W，Chang R，Zhong J，et al.Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression［J］.Proc Natl Acad Sci USA，2012，109(49)：E3367-3376.
［40］Garayoa M，Martínez A，Lee S，et al.Hypoxia-inducible factor-1(HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation：A possible promotion mecha-nism of carcinogenesis［J］.Mol Endocrinol，2000，14(6)：848-862.
［41］Chang J，Erler J.Hypoxia-mediated metastasis［J］.Adv Exp Med Biol，2014，772：55-81.
［42］Saggar JK，Yu M，Tan Q，et al.The tumor microenvironment and strategies to improve drug distribution［J］.Front Oncol，2013，3：154.
［43］Ceradini DJ，Kulkarni AR，Callaghan MJ，et al.Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1［J］.Nat Med，2004，10(8)：858-864.
［44］Semenza GL.HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations［J］.J Clin Invest，2013，123(9)：3664-3671.
［45］Aalders KC，Tryfonidis K，Senkus E，et al.Anti-angiogenic treatment in breast cancer：Facts，successes，failures and future perspectives［J］.Cancer Treat Rev,2017，53：98-110.
［46］Hu Y，Liu J，Huang H.Recent agents targeting HIF-1alpha for cancer therapy［J］.J Cell Biochem，2013，114(3)：498-509.
［47］Cleator S,Heller W，Coombes RC.Triple-negative breast cancer：Therapeutic options［J］.Lancet Oncol，2007，8(3)：235-244.
［48］Xiang L，Gilkes DM，Chaturvedi P，et al.Ganetespib blocks HIF-1 activity and inhibits tumor growth，vascularization，stem cell maintenance，invasion，and metastasis in orthotopic mouse models of triple-negative breast cancer［J］.J Mol Med(Berl)，2014，92(2)：151-164.
［49］Liapis V，Zinonos I，Labrinidis A，et al.Anticancer efficacy of the hypoxia-activated prodrug evofosfamide(TH-302) in osteolytic breast cancer murine models［J］.Cancer Med，2016，5(3)：534-545.
［50］Samanta D，Gilkes DM，Chaturvedi P，et al.Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells［J］.Proc Natl Acad Sci USA，2014，111(50)：E5429-5438.
［51］Moore SC，Lee IM，Weiderpass E，et al.Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults［J］.JAMA Intern Med，2016，176：816-825.
［52］Cummings SR，Tice JA，Bauer S，et al.Prevention of breast cancer in postmenopausal women：Approaches to estimating and reducing risk［J］.J Natl Cancer Inst，2009，101(6)：384-398.
［53］Jones LW，Viglianti BL，Tashjian JA，et al.Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer［J］.J Appl Physiol(1985)，2010，108(2)：343-348.
［54］Holick CN，Newcomb PA，Trentham-Dietz A，et al.Physical activity and survival after diagnosis of invasive breast cancer［J］.Cancer Epidemiol Biomarkers Prev，2008，17(2)：379-386.
［55］Hardman WE，Sun L，Short N，et al.Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogen-esis［J］.Cancer Cell Int，2005，5(1)：12.
［56］Myrte C，Elisabeth A，Diede Verlaan，et al.The mechanisms and effects of physical activity on breast cancer［J］.Clinical Breast Cancer，2017，17(4)：272-278.